Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
The main objective of the study is the assessment of the overall graft rejection rate (acute, chronic and subclinical) between a treatment with ATG-Fresenius administered in addition to standard treatment consisting of CellCept® or Myfortic®/TAC and without corticosteroids and a treatment consisting of CellCept® or Myfortic®/TAC and corticosteroids during the first year after renal transplantation.
Epistemonikos ID: dceea35bde076c4d2e32b81a9f20b6b3e359f09a
First added on: May 06, 2024